Your session is about to expire
← Back to Search
Imaging
Dixon MRI for Prostate Cancer
N/A
Waitlist Available
Led By Ganeshan Dhakshina Moorthy
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Biopsy proven prostate cancer patients who are scheduled to undergo prostatectomy
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year
Awards & highlights
Study Summary
This trial uses MRI with Dixon-based imaging to detect prostate cancer. Researchers hope to learn if this will produce better images than the standard MRI scan.
Who is the study for?
This trial is for men with biopsy-proven prostate cancer who have consented to participate, are scheduled for prostate removal surgery (prostatectomy), and a standard MRI scan. It's not open to those who've had hormone or radiation therapy affecting the pelvis or prostate, prefer other treatments over surgery, or can't have MRIs due to metal implants or pacemakers.Check my eligibility
What is being tested?
The study is testing whether a modified MRI technique using Dixon based imaging sequences can provide better images of prostate cancer compared to the usual MRI scans. The goal is to see if this new scanning method improves the detection and visualization of prostate tumors.See study design
What are the potential side effects?
Since this trial involves an investigational imaging technique rather than a drug, there are no direct side effects like you'd expect from medication. However, typical MRI-related concerns such as discomfort from lying still may occur.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have prostate cancer confirmed by biopsy and will have surgery to remove my prostate.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Detection of at least one or more prostate lesions with Dixon sequencing
Side effects data
From 2022 Phase 3 trial • 53 Patients • NCT0003329319%
87900-Vomiting(targeted toxicity)
15%
11400-Agitation
8%
11600-Alanine aminotransferase increased
8%
16800-Bladder infection
8%
44800-Infections and infestations - Other specify
8%
58700-Nystagmus
4%
15000-Aspartate aminotransferase increased
4%
88500-White blood cell decreased
4%
15300-Ataxia
4%
33900-Fever
4%
25700-Diarrhea
4%
43100-Hypokalemia
4%
69700-Rash maculo-papular(targeted toxicity)
4%
13200-Anemia
4%
33300-Febrile neutropenia
4%
57600-Nausea(targeted toxicity)
4%
20500-Catheter related infection
4%
58300-Neutrophil count decreased
4%
41300-Hypercalcemia
4%
41400-Hyperglycemia(targeted toxicity)
4%
41600-Hyperkalemia
4%
42600-Hypoalbuminemia
4%
42700-Hypocalcemia
4%
64400-Personality change
4%
41500-Hyperhidrosis
4%
13500-Anorexia
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm I (Chemotherapy, Immunoglobulin Therapy)
Arm II (Chemotherapy, Observation)
Trial Design
1Treatment groups
Experimental Treatment
Group I: Diagnostic (standard MRI, Dixon MRI)Experimental Treatment2 Interventions
Patients undergo MRI with additional Dixon based sequences with fat and water over a total of 49 minutes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Magnetic Resonance Imaging
2017
Completed Phase 3
~1190
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,976 Previous Clinical Trials
1,789,443 Total Patients Enrolled
95 Trials studying Prostate Cancer
29,675 Patients Enrolled for Prostate Cancer
National Cancer Institute (NCI)NIH
13,687 Previous Clinical Trials
40,930,306 Total Patients Enrolled
563 Trials studying Prostate Cancer
508,771 Patients Enrolled for Prostate Cancer
Ganeshan Dhakshina MoorthyPrincipal InvestigatorM.D. Anderson Cancer Center
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have prostate cancer confirmed by biopsy and will have surgery to remove my prostate.I have had hormone therapy or radiation for my pelvic or prostate area.I prefer not to have surgery for my prostate condition.I am scheduled for a prostate MRI to check the cancer stage.
Research Study Groups:
This trial has the following groups:- Group 1: Diagnostic (standard MRI, Dixon MRI)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there still opportunities to become involved in this scientific investigation?
"The clinical trial, initially posted on April 25th 2013 and last updated on September 8th 2021 is not recruiting patients. However, there are an abundance of other medical studies currently enrolling new participants."
Answered by AI
Share this study with friends
Copy Link
Messenger